

### List of References Cited by Applicant

<b>Atty Docket No.:</b>	13783-105023		
<b>Applicant (s):</b>	Koenig et al.	<b>Serial No.:</b>	10/524,134
<b>Filing Date:</b>	February 11, 2005	<b>Group Art Unit:</b>	1644

### U.S. PATENT DOCUMENTS

Examiner Initial		Document No.	Date	Name	Class	Subclass	Filing Date if appropriate
	A18	6,737,056	5/18/2004	Presta			
	A19	2004/0002587	1/1/2004	Watkins et al.			
	A20	2004/0185045 A1	9/23/2004	Koenig et al.			
	A21	2005/0037000 A1	2/17/2005	Stavenhagen et al.			
	A22	2005/0215767	9/29/2005	Koenig et al.			
	A23	2005/0260213 A1	11/24/2005	Koenig et al.			
	A24	2006/0013810	1/19/2006	Johnson et al.			
	A25	2006/0073142	4/6/2006	Chan et al.			
	A26	2006/0177439	8/10/2006	Koenig et al.			
	A27	2007/0253948	11/1/2007	Chan et al.			
	A28	11/754,015		Johnson et al.			5/25/2007
	A29	11/768,852		Johnson et al.			6/26/2007

### FOREIGN PATENT DOCUMENTS

Examiner Initial		Document No.	Date	Country	Class	Subclass	Translation Yes/No
	B15	WO 04/016750 A2	2/26/2004	PCT			
	B16	WO 05/110474 A2	11/24/2005	PCT			
	B17	WO 05/115452 A2	12/08/2005	PCT			
	B18	WO 06/066078 A2	6/22/2006	PCT			
	B19	PCT/US07/72151		PCT; filing date: June 26, 2007			

### OTHER REFERENCES *(Including Author, Title, Date, Pertinent Pages, Etc.)*

	C83	Boruchov et al., Activating and inhibitory IgG Fc receptors on human DCs mediate opposing functions. The Journal of Clinical Investigation 115; 10:2914-2923.
	C84	Ott et al. FcγRIIB as a potential molecular target for intravenous gamma globulin therapy. J Allergy Clin Immunol. 2001; 108:S95-S98.

	C85	Pardridge et al., Blood-brain barrier drug targeting: The future of brain drug development. Molecular Interventions. 2003, 3;2:90-105. See particularly pages 91-96.
	C86	Reff et al. A review of modifications to recombinant antibodies: attempt to increase efficacy in oncology applications. Crit Rev Oncol Hematol. 2001; 40(1):25-35
	C87	Su et al., Expression profile of FcγRIIB on leukocytes and its dysregulation in systemic lupus erythematosus. J. Immunol. 178:3272-3280, 2007

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	